©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Multiple Neuron-specific Enhancers in the Gene Coding for the Human Neurofilament Light Chain (*)

(Received for publication, June 29, 1995; and in revised form, October 27, 1995)

Guy Charron Louis-Georges Guy Martine Bazinet Jean-Pierre Julien (§)

From the Centre for Research in Neuroscience, McGill University, The Montreal General Hospital Research Institute, Montréal, Quebec H3G 1A4, Canada

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

To define DNA regions involved in the neuron-specific expression of the neurofilament light (NF-L) gene, we generated transgenic mice bearing different NF-L constructs. A 4.9-kilobase human NF-L fragment including -292 base pairs of 5`-flanking sequences contained sufficient elements for nervous system expression in transgenic mice. Deletion of introns 1 and 2 from this 4.9-kilobase DNA fragment resulted in reduced levels of transgene expression in the cortex, while deletion of intron 3 had little effect. Both introns 1 and 2 could act independently as enhancers to confer neuronal expression of the basal heat shock promoter (hsp68) fused to lacZ in transgenic mice. The hNF-L basal promoter (-292 base pairs) was found to contain elements for directing neuronal expression of either the lacZ reporter gene or an intronless hNF-L construct. Sequence comparison revealed that intron 1, intron 2, and the basal human NF-L promoter all contain an ETS-like motif, CAGGA, present in a variety of genes expressed in the nervous system.


INTRODUCTION

Neurofilaments are formed by the copolymerization of three neuron-specific proteins with an apparent molecular mass on SDS gel of 70 kDa (NF-L), 150 kDa (NF-M), and 200 kDa (NF-H)(1, 2, 3) . The genes coding for the three NF (^1)proteins have been cloned and sequenced(4, 5, 6, 7, 8, 9, 10) . Like other intermediate filaments (IF) genes, NF genes are expressed in a cell type-specific and developmental manner(11, 12, 13) . IF genes, from class IV and VI, are differentially regulated during the development of neuronal progenitor cells(5, 9, 14, 15, 16) .

Neurofilaments are expressed in most neurons of the nervous system, and their expression coincides with terminal neuronal differentiation. There is growing evidence that deregulation of neurofilament expression may play a central role in motor neuron disease. Transgenic mice that overexpress neurofilament proteins show motor neuron degeneration (17, 18, 19, 20, 21) . Furthermore, the levels of NF-L mRNA are decreased in dogs with hereditary canine spinal muscular atrophy (22) as well as in motor neurons of patients with amyotrophic lateral sclerosis(23) . Yet, little is known about the mechanisms that regulate expression of neurofilament genes in the nervous system. This is in part due to the lack of suitable in vitro systems to study their expression (15) . For instance, high levels of NF-L expression occurred after transfection of a complete genomic NF-L gene in non-neuronal cells such as cultured fibroblasts(6, 24) , even though the endogenous NF-L gene remained silent. In contrast, DNA fragments containing either the complete human or mouse NF-L genes were correctly expressed in transgenic mice(25, 26) .

We have shown previously that a human NF-L fragment including -292 bp of 5`-flanking sequences and intron sequences contained sufficient elements to drive NF-L expression in the nervous tissues of adult transgenic mice(27) . To further clarify the potential role of introns in modulating expression of the human NF-L gene, we used the transgenic mouse approach to test the transcriptional activity of NF-L DNA regions. We report here the existence of neuron-specific enhancers in both introns 1 and 2, which contribute to a wider expression pattern of the NF-L gene. In addition, we show that the regulatory elements included in the NF-L basal promoter (-292 bp) are sufficient to target neuronal expression.


EXPERIMENTAL PROCEDURES

Plasmid Construct

To delete introns of the hNF-L gene, we took advantage of the existence of conserved restriction sites between the human and mouse NF-L genes. First, a 4.9-kb BamHI-XbaI fragment including the human NF-L gene was subcloned into the corresponding sites of a Bluescript pSK+ vector giving plasmid pSKhNF-L(27) . The pSKhNF-L plasmid was subjected to a total BglII digestion followed by a partial SacI digestion, resulting in deletion of a DNA fragment spanning intron 1 and 2 all together with part of exon 1 and 3. The remaining plasmid pSKhNF-L was then isolated on agarose gel. A corresponding DNA BglII-SacI fragment of 750 bp from the mouse cDNA (5) was subcloned in that vector to recreate a human-mouse hybrid NF-L gene with its complete coding sequences but lacking introns 1 and 2 (construct hNF-L/intron3). A similar approach was used to delete intron 3, except that a double SacI-EcoRI partial digestion was carried out. The 522-bp SacI-EcoRI fragment from the mouse cDNA was used to replace the third intron. For the hNF-L/intronless and the intronless-UTR, the pSKhNF-L was digested to completion by BglII followed by a partial EcoRI digestion. From the mouse cDNA clone 646(5, 13) , a BglII-EcoRI fragment of 1200 bp was isolated and ligated to the open pSKhNF-L vector. Prior to microinjection, all deletion mutant constructs were isolated on agarose gel after complete BamHI-XbaI digestion except for the intronless/UTR, the DNA fragment was isolated after enzymatic digestion with BamHI-PacI. The PacI restriction site is localized 35 bp after the first polyadenylation signal of the human NF-L gene.

The beta-galactosidase gene (lacZ) was obtained from plasmid pCH110 (Pharmacia Biotech Inc.). The pCH110 was cut to completion with HindIII followed by EcoRI partial digestion. A fragment of 4486 bp was then isolated and subcloned into Bluescript pSK+ linearized with HindIII-EcoRI digestion, creating plasmid pSKlacZ. The human NF-L basal promoter (from -292 to +15 bp) was isolated, blunted, and ligated to HindIII linker prior to insertion into HindIII site in pSKlacZ giving hNF-L/lacZ construct. A XhoI-NotI DNA fragment of 4.8 kb was isolated on agarose gel for microinjection.

To prepare the hsp-lacZ construct, we subcloned a lacZ enhancer trap vector (28) into the BamHI sites of a Bluescript SK+ plasmid (Stratagene). Each intron was then amplified by PCR and inserted into the unique SmaI site localized at the 5`-end of the cassette. For microinjection, each construct was separated from plasmid sequences on agarose gel after digestion with SalI-NotI.

Microinjection into One-cell Mouse Embryos

Linear DNA fragments were isolated and diluted to concentration of 1 µg/ml in Tris-HCl, pH 7.5, 0.15 mM EDTA prior to microinjection into male pronuclei of C57Bl/6J X C3H fertilized eggs. Injected embryos were transferred to the oviduct of pseudopregnant females(29) . Identification of transgenic mice was carried out by Southern blot analysis of 10 µg of tail genomic DNA as described before(27, 30) .

RNase Protection Assay

RNA was prepared from various tissues of transgenic mice by the guanidinium/phenol method (31) . A 958-bp BglII fragment spanning exon 1 and intron 1 sequences of the human NF-L gene was subcloned into the pT7/T3-18 vector (Life Technologies, Inc.). After linearization of the plasmid with HindIII, an antisense RNA probe of high specific radioactivity was generated with T7 RNA polymerase in the presence of [alpha-P]CTP. An excess of RNA probe was hybridized at 45 °C with 15 µg of total RNA, and RNase treatment was carried out at 34 °C as described previously(32) . RNase-protected fragments were resolved on denaturing 5% polyacrylamide gels. P-Labeled ladder (Life Technologies, Inc.) served as markers.

RT-PCR

20 µg of total mRNA was resuspended in 4 volumes of H(2)O prior to ethanol precipitation. Pellets were resuspended in 46 µl of buffer A (100 mM KCl, 20 mM Tris-HCl (pH 8.0 at 25 °C), 10 mM (NH(4))(2)SO(4), 10 mM MgCl(2), 0.1% Triton X-100). The first strand synthesis was performed by adding 8 µl of 1.25 mM dNTP mix and 250 ng of primers 784 and 808 in presence of 30 units of RNAguard and 20 units of avian myeloblastosis virus reverse transcriptase. Reaction mixture was incubated at 42 °C during 1 h and then stopped at 95 °C for 5 min. Each sample was subjected to two PCR reactions, one specific for the hNF-L transcript using primer 522 and 784 and the others to the G3PDH transcript using primers 808 and 809. The PCR reaction was done according to the manufacturer (New England Biochemicals) using of the cDNA mix as template, 0.20 µCi of [P]dATP, and 1 unit of VENT DNA polymerase. After 25 cycles (1 min at 95 °C, 1 min at 55 °C, 1 min at 72 °C), an aliquot of both PCR-specific reactions was electrophoresed on 1% agarose gel, blotted, and autoradiographed.

Oligonucleotides

Primers 522 and 784 are specific for the first hNF-L exon. Their sequences are, respectively, GCACATCTCCAGCGTGCGT and AGATCTGCGCGTACTGGATCTGCGCC. A second pair of oligonucleotides specific for the mouse G3PDH mRNA has served to quantified amounts of RNA in each sample. Their sequences are TTGATGGTATTCGAGAGAAGGG (primer 808) and TCCAGGAGCGAGATCCCGTC (primer 809).

Histochemical Staining for beta-Galactosidase

The 13.5-day-old embryos were fixed in 4% paraformaldehyde in 0.8% NaCl, KCl, Na(2)HPO(4), KH(2)PO(4) (PBS) for 90 min at 4 °C. Fixed embryos were then washed at 4 °C in three changes of PBS and incubated at 30 °C overnight in a solution containing 1 mg/ml X-Gal, 5 mM K(4)Fe(CN)(6), 5 mM K(3)Fe(CN)(6), 2 mM MgCl(2), 0.01% sodium deoxycholate, and 0.02% Nonidet P-40 in PBS. After staining, some specimens were prepared for section examination by first incubation at 4 °C for 1 h in PBS containing 10% sucrose and then overnight in PBS added with 15% sucrose. Embryos were embedded in Tissu-tek and frozen in isopentane cooled with liquid nitrogen. Sections (15-20 µm thick) were cut on cryostat at -22 °C and recovered on Superfrost+ microscope slides (Fisher).


RESULTS

Transcriptional Activity of NF-L Intron Sequences

To determine the specific contribution of intragenic sequences on transcriptional regulation of the hNF-L gene, we generated transgenic mice with various DNA constructs in which introns were deleted in various combinations (Fig. 1). The presence, in exon sequences, of conserved restriction sites between the human and mouse NF-L genes allowed us to selectively swap genomic regions of the human NF-L gene with fragments of the mouse NF-L cDNA. All deletion mutants included the basal human NF-L promoter (-292 bp) and the first endogenous hNF-L polyadenylation signal.


Figure 1: Schematic representation of NF-L DNA constructs. Internal deletion mutants were produced using a human NF-L gene fragment (hNF-L) (-292 to +4605) in which intragenic regions were replaced by corresponding regions of a mouse NF-L cDNA (see ``Experimental Procedures''). The solid boxes represent the human NF-L exons, while the double-hatched boxes represent mouse NF-L cDNA sequences. The hatched boxes represent the 3`-untranslated regions. Restriction enzyme cutting sites are as follows: B, BamHI; Bg, BglII; RI, EcoRI; Sac, SacI; X, XbaI.



Four transgenic mouse lines have been generated with the intact 4.9-kb hNF-L gene (Fig. 2). In only one mouse line, the transgene remained silent in all tissues examined. In the other three mouse lines, expression of the NF-L transgene, as detected by RNase protection assay, was restricted to the nervous system. Fig. 3A shows the results of a RNase protection experiment carried out with RNA from an adult mouse of line 1 using an antisense RNA probe covering the first hNF-L exon/intron border.


Figure 2: Summary of data generated with five different NF-L gene constructs in 16 transgenic mouse lines. ND signifies that RNA samples were not analyzed; the number of + symbols gives a relative quantification of the intensity of NF-L mRNA expression, while empty boxes indicate absence of expression. The mouse lines presented in Fig. 3and Fig. 4are labeled with a asterisk.




Figure 3: Expression analysis of an NF-L transgene lacking intron 3. Total RNA from various tissues of transgenic mice bearing a complete hNF-L gene (panel A) and the hNF-L/intron1,2 construct (panel B) was analyzed by an RNase protection assay for specific expression of human NF-L transcripts. The antisense RNA probe of 960 bp spanning the first hNF-L exon/intron boundary yields a protected fragment of 316 nucleotides. The control mRNA (lane 15 in B) was obtained from the mouse line 29 expressing a 21.1-kb human NF-L fragment(18) . The negative control (lane 14) corresponds to total cortex mRNA from a normal mouse. B, BamHI; Bg, BglII; RI, EcoRI; Sac, SacI; X, XbaI.




Figure 4: Expression analysis of NF-L transgenes by an RT-PCR assay. Total mRNA from various tissues of transgenic mice was reverse transcribed prior to PCR assay. Two sets of oligonucleotides were used. The first set corresponds to oligonucleotides specific for the first exon of the human NF-L gene, and they do not amplify mouse NF-L transcripts. The second pair corresponds to the mouse G3PDH gene, which is used as an internal control. Lane 1, amplified product from mRNA of normal mouse cortex; lanes 2-11, mRNA from a hNF-L transgenic mouse; lanes 12-21, mRNA from mice with hNF-L/intron3 transgene; lanes 22-31, mRNA from mice with hNF-L/intronless; and lanes 32-41, mRNA from mice with intronless-UTR.



With the hNF-L/intron1,2 transgene, two out of three mouse lines expressed the transgene (Fig. 2). RNase protection analysis of the RNA from offspring revealed, in both mouse lines, a restricted expression to nervous system (Fig. 3B). In one transgenic line, ectopic expression occurred in the heart (Fig. 2).

For analysis of the hNF-L/intron3, hNF-L/intronless, and the intronless/UTR constructs, the 960-bp human RNA probe could not be used since the human exon 1 sequences have been replaced by the corresponding mouse sequences. Therefore, to analyze transgene expression, we carried out an RT-PCR assay with a set of oligonucleotides specific for the 5`-part of the hNF-L first exon (Fig. 4A). The corresponding endogenous NF-L mRNA is not amplified with these primers (Fig. 4B, lane 1) because of species differences in the 5`-untranslated sequences. For the hNF-L/intron3, hNF-L/intronless, and the intronless-UTR, a total of nine different transgenic mouse lines were produced, of which seven expressed their transgene (Fig. 2). All three DNA constructs yielded a restricted expression to nervous tissue. Only line 12, generated with the hNF-L/intronless construct, showed a signal in the heart (Fig. 4B, lane 30).

The removal of introns 1 and 2 resulted in decreased levels of transgene expression in the cortex and cerebellum as detected by RT-PCR (Fig. 4A, compare lane 12 with lane 2). Further deletion of intron 3 and 3`-UTR had little effect on expression pattern and intensity of the bands (Fig. 4B). These results suggested that introns 1 and 2 do contain regulatory elements that contribute to the enhancement of hNF-L expression in the cortex and cerebellum of adult mouse.

Neuron-specific Expression of a lacZ Reporter Gene Driven by the hNF-L Basal Promoter

The above experiment with the hNF-L/intronless suggested that basal NF-L promoter(-292) was able to direct specific expression in the nervous system. Paradoxally, we reported previously that the same promoter was unable to direct neuronal expression of the chloramphenicol acetyltransferase reporter gene. To further clarify the activity of this promoter (-292 to +15 bp), we tested it on the widely used Escherichia coli beta-galactosidase reporter gene (lacZ). Four transgenic founders were obtained with the hNF-L/lacZ construct, of which three expressed the transgene. The 13.5-day-old embryos were stained with X-Gal. A blue coloration, indicative of lacZ expression, was found predominantly in the nervous system (Fig. 5). We noted a slight variability in the expression patterns from one embryo to another (Fig. 5), likely reflecting an influence of the chromosomal integration site. This phenomenon, which has been observed for other transgenes(33, 34) , can result from the absence of dominant control elements that confer position-independent expression like those found in the beta-globin gene(35) . Microscopic analysis performed on adult brain sections of line 1 showed expression to diverse population of neurons (Fig. 6). In the cortex, lacZ staining was localized in the forelimb and hindlimb area of the cortex (Fig. 6A) in neurons of the cingulum (Fig. 6C), the lateral septal (Fig. 6D), the piriform cortex (Fig. 6E), and in the hippocampus (Fig. 6F). Strong staining was found in neurons of the granule cell layer of the cerebellum (Fig. 6G). Some neurons of the molecular layer were colored, but no Purkinje cells were stained. lacZ expression was found in the dorsal horn region of the spinal cord and in the dorsal root ganglia (Fig. 6, H and I, respectively). In all regions of the nervous system, only a subset of neurons was stained. The combined results indicate that the basal hNF-L promoter does contain transcriptional elements capable to direct neuron-specific expression in both embryos and adult mice.


Figure 5: Neuron-specific regulatory elements in the NF-L gene direct heterologous lacZ expression. Embryos were analyzed 13.5 days after microinjection of lacZ DNA constructs. At left is shown a schematic representation of each lacZ fusion construct. An times indicates the stained tissues, and the arrow at the end of the line indicates the embryos from which pictures were taken. At right are photographs of embryos from side, back, and front.




Figure 6: Histological detection of beta-galactosidase in an hNF-L/lacZ transgenic mouse. The brain was dissected from adult F1 transgenic of mouse line 1 (see Fig. 5) after perfusion with 4% paraformaldehyde in PBS. The lacZ staining was performed overnight on 3-mm-thick tissue slices. Frozen sections (15-20 µm) were collected in a cryostat, counter-stained with neutral red, mounted, and pictured. Overview of a near-midline sagital and transversal brain section is shown (A and B, respectively). Panels showing a higher magnification are as follows: C, the cingulum region (transversal section); D, the lateral septum (transversal section); E, the hyppocampus (sagital section); and F, the cerebellum (sagital section). Transversal sections through the spinal cord dorsal horn (G) and the dorsal root ganglia (H) are shown; olfactory nuclei (I) is also shown. Pl, Purkinje cell layer; Ml, molecular layer; Gl, granule cell layer; V, ventricule; LS, lateral septum; Cg, cingulum; Ep, ependimis.



Neuron-specific Enhancers in Human NF-L Introns

The data presented above suggested the existence of regulatory elements within introns of the human NF-L gene. To further confirm the presence of regulatory elements in introns, the DNA fragments spanning intron sequences were tested for their activity using a hsp68/lacZ enhancer trap vector. This vector is composed of the basal promoter of the gene for the heat shock protein hsp68, followed by the E. coli beta-galactosidase gene. The minimal hsp68 promoter exhibited no basal activity in transgenic mice (36) unless a heterologous enhancer was placed in its vicinity(28, 37, 38) . Thus, the transcriptional activation of the basal hsp promoter reflects the activity of elements carried by a heterologous enhancer. The hNF-L introns 1, 2, and 3 were amplified by PCR and subcloned independently in front of the hsp68/lacZ enhancer trap vector to yield constructs, designated int-1, int-2, and int-3, respectively.

Whole mount transgenic embryos were analyzed for expression of those constructs at 13.5 days post-fertilization. With the int-1 construct, four distinct founders were generated. All four lines expressed the lacZ transgene in the nervous tissue (Fig. 5). A mild variation in the pattern of nervous system expression was detected from one line to another. One embryo showed ectopic expression in the limb buds, while another yielded a very weak signal in the somites. Similarly, the five transgenic embryos bearing the int-2 construct presented a variegated staining in the nervous system. Only one embryo revealed ectopic expression to the apical ectoderm ridge. Of the six transgenic embryos generated with the int-3 construct, none yielded lacZ expression in the nervous system. Ectopic expression was detected at low levels in three lines (Fig. 5).

These results demonstrated the existence of neuron-specific enhancers located in the first and second NF-L introns that can contribute to enhance NF-L expression in the telencephalon, diencephalon, and mesencephalon that correspond to anterior structure of the embryonic nervous system (Fig. 5). The third intron is apparently devoid of such elements. To further define enhancer regions in the first intron, we generated a construct named 5`int-1 (Fig. 5), in which the first 560-bp region of intron 1 was subcloned in front of the hsp68/lacZ gene construct in an opposite orientation (Fig. 5). Two transgenic embryos were obtained, and they both expressed lacZ in the nervous system. Our conclusion is that the 5`-region of intron 1 contains elements to enhance expression in the anterior region of the nervous system.


DISCUSSION

We report here that the minimal human NF-L promoter (-292 bp) is sufficient to direct neuronal expression both of an hNF-L/intronless and an hNF-L/lacZ reporter gene ( Fig. 4and Fig. 5). Although a variegated staining occurred in transgenic embryos generated with the hNF-L/lacZ transgene, the lacZ activity was limited to the nervous tissue. This variegation is likely due to an influence of the chromosomal integration site, as chromatin assembly and/or neighboring regulatory elements could affect transcriptional activity. The neuronal expression of the hNF-L/lacZ fusion construct was an unexpected finding, as this same promoter was previously found to be unable to direct neuron-specific expression of the chloramphenicol acetyltransferase reporter gene(27) . How could different reporter genes yield different results? It is well known that folding of the DNA in a nucleosomal structure generally decreases basal transcriptional activity (for review, see (39) ). Elements capable to initiate loop domain formation, such as matrix attachment regions, can alleviate this phenomenon. We recently demonstrated the presence of matrix attachment regions with DNA unwinding element in the 3`-untranslated region of the hNF-L and lacZ genes but not in the chloramphenicol acetyltransferase gene(40) . Following deletion of matrix attachment region sequences from the lacZ gene, the hNF-L/lacZ construct became susceptible to position effect, and its expression was no longer tissue specific(40) .

The removal of introns 1 and 2 in the human NF-L gene resulted in a decrease of transgene expression in the cortex and cerebellum of adult mouse. The presence of regulatory elements in introns 1 and 2 was further confirmed using the hsp68/lacZ enhancer trap vector. Both introns acted as enhancers inducing neuronal expression of the hsp68 minimal promoter in a position- and orientation-independent fashion. As shown in Fig. 5, intron 1 directed hsp68/lacZ expression mainly to the telencephalon, diencephalon, and mesencephalon. The intron 1 enhancer responsible for expression to anterior structure of embryonic nervous system is located in 5`-region of this intron (Fig. 5, construct 5`int-1). The presence of regulatory elements within introns of the human NF-L gene is consistent with the mapping of the DNase I hypersensitive sites (HS) reported by Yazdanbaksh et al.(41) . These investigators located three different neuron-specific DNase I hypersensitive sites in the 5`-flanking region (HS1, -2, -3) and four within the human NF-L gene (HS4, -5a, -5b, -6). Except for HS4, located in exon 1, all other intragenic hypersensitive sites are located within introns. The HS5a and 5b are positioned at the 5`-region of intron 1 shown here to contain elements for neuronal expression, while HS6 is located at the end of intron 2.

It is noteworthy that the positions of introns 1 and 2 are conserved among all intermediate filament genes of class IV and VI. It has been postulated that genes of class IV and VI, which correspond to the neuronal branch of the IF family, arose by a reverse transcription of an mRNA from an ancestral lamin-like gene(42) . Recently, Zimmerman et al.(43) demonstrated that elements regulating mesodermal and neuronal transcription of the nestin gene, an IF protein of class VI, reside in the first and second introns at positions equivalent to intron 1 and 2 in the NF-L gene. It is thus conceivable that the acquisition of introns by an intronless progenitor gene may have led to the emergence of a lineage of IF genes expressed in the nervous system.

A computer search was carried out to identify known cis-regulatory elements within the promoter and introns of the human NF-L gene. Elements like NF-E1, HOX type 1, and the PEA3 sequences are present in both introns 1 and 2 (Fig. 7). None of these cis regulatory elements can explain neuronal specificity. The mRNA coding for the ETS transcription factor PEA3 is detected in mouse brain, but its expression is not exclusive to this tissue(44) . We note, however, that the sequence CAGGA, which includes part of the core consensus AGGAA recognized by the family of ETS transcription factors(45) , is present in numerous neuron-specific genes including the genes for NF-M(8, 46) , NF-H, (^2)alpha-internexin(15) , peripherin(47) , Drosophila dopa decarboxylase(48, 49) , chicken alpha7-nicotinic acetylcholine receptor(50) , mouse olfactory marker protein(51) , rat neuron-specific enolase encoding gene(52) , Purkinje-cell-protein-2 encoding gene(53) , the gene encoding the growth cone-associated protein SCG10(54) , and type II sodium channel encoding gene(55) . Most known members of the ETS family are expressed in lymphoid tissue, but other ETS-related factors are also expressed in neurons(56) . We recently reported that an ETS-like element located at -908 in the human NF-L 5`-region is recognized by a factor expressed in P19 cells differentiated into neurons(56) . Moreover, two neuron-specific DNase I hypersensitive sites border this element(41) . Our combined results suggest an implication for ETS-related transcription factors in the control of neuron-specific expression. Mutational analysis of the ETS-like elements in the NF-L gene should establish their specific contributions to expression of this gene in the nervous system.


Figure 7: Potential regulatory elements in the human NF-L and transcription factor binding sites found in the regulatory region of the human NF-L. The analysis was done on hNF-L regions -292 to +15 (basal promoter), +1225 to +2323 (intron 1), and +2450 to 2834 (intron 2) using the GCC program with the TFD data base from GenBank. No mismatches were allowed with consensus sequences.




FOOTNOTES

*
This work was supported in part by the Medical Research Council of Canada and the Canadian Network of Center of Excellence in NeuroScience. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank(TM)/EMBL Data Bank with accession number(s) X05608[GenBank].

§
To whom correspondence should be addressed: Montreal General Hospital Research Institute, 1650 Cedar Ave., Montreal, Québec H3G 1A4, Canada. Tel.: 514-937-6011 (ext. 2361); Fax: 514-934-8265.

(^1)
The abbreviations used are: NF, neurofilament; NF-L, neurofilament light; bp, base pair(s); kb, kilobase(s); hNF-L, human neurofilament light; UTR, untranslated region; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase PCR; HS, hypersensitive sites; PBS, phosphate-buffered saline.

(^2)
J.-P. Julien, unpublished data.


ACKNOWLEDGEMENTS

We thank Catherine Grandjean for technical assistance. The help of Daniel Houle, Gaétan Gagnon, and Debby Altschuller for the production and breeding of transgenic mice is gratefully acknowledged.


REFERENCES

  1. Hoffman, P. N., and Lasek, R. J. (1975) J. Cell Biol. 66, 351-366 [Medline]
  2. Liem, R. K. H., Yen, S.-H., Salomon, G. D., and Shelanski, M. L. (1978) J. Cell Biol. 79, 637-645 [Medline]
  3. Geisler, N., and Weber, K. (1981) J. Mol. Biol. 151, 565-571 [Medline]
  4. Lewis, S. A., and Cowan, N. J. (1986) Mol. Cell. Biol. 6, 1529-1534 [Medline]
  5. Julien, J.-P., Meijer, D., Hurst, J., and Grosveld, F. (1986) Mol. Brain Res. 1, 243-250
  6. Julien, J.-P., Grosveld, F., Yazdanbaksh, K., Flavell, D., Meijer, D., and Mushynski, W. (1987) Biochim. Biophys. Acta 909, 10-20
  7. Julien, J.-P., Côté, F., Beaudet, L., Flavell, D., Grosveld, F., and Mushynski, W. E. (1988) Gene (Amst.) 68, 307-314 [Medline]
  8. Levy, E., Liem, R. K. H., D'Eustachio, P., and Cowan, N. J. (1987) Eur. J. Biochem. 166, 71-77 [Medline]
  9. Myers, M. W., Lazzarini, R. A., Lee, V. M.-Y., Schlaepfer, W. W., and Nelson, D. L. (1987) EMBO J. 6, 1617-1626 [Medline]
  10. Lees, J. F., Shneidman, P. S., Skuntz, S. F., Carden, M. J., and Lazzarini, R. A. (1988) EMBO J. 7, 1947-1955 [Medline]
  11. Osborn, M., and Weber, K. (1982) Cell 31, 303-306 [Medline]
  12. Cochard, P., and Paulin, D. (1984) J. Neurosci. 4, 2080-2094 [Medline]
  13. Liesi, P., Julien, J.-P., Vilja, P., Grosveld, F., and Rechardt, L. (1986) J. Histochem. Cytochem. 34, 923-929 [Medline]
  14. Lendahl, U., Zimmerman, L. B., and McKay, R. D. G. (1990) Cell 60, 585-595 [Medline]
  15. Ching, G. Y., and Liem, R. K. H. (1991) J. Biol. Chem. 266, 19459-19468 [Medline]
  16. Lieberburg, I., Spinner, N., Snyder, S., Anderson, J., Goldgaber, D., Smulowitz, M., Carroll, Z., Emanuel, B., Breitner, J., and Rubin, L. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2463-2467 [Medline]
  17. Côté, F., Collard, J.-F., and Julien, J.-P. (1993) Cell 73, 35-46 [Medline]
  18. Xu, Z. Cork, L., Griffin, J. W., and Cleveland, D. W. (1993) Cell 73, 23-33 [Medline]
  19. Lee, M. K., Marszalek, J. R., and Cleveland, D. W. (1994) Neuron 13, 975-988 [Medline]
  20. Collard, J.-F., Côté, F., and Julien, J.-P. (1995) Nature 375, 61-64 [Medline]
  21. Julien, J.-P., Côté, F., and Collard, J.-F. (1995) Neurobiol. Aging 16, 487-492 [Medline]
  22. Muma, N., and Cork, L. (1993) Lab. Invest. 69, 436-442 [Medline]
  23. Bergeron, C., Beric-Maskarel, K., Muntasser, S., Weyer, L., Somerville, M. J., and Percy, M. E. (1994) J. Neuropathol. Exp. Neurol. 53, 221-230 [Medline]
  24. Monteiro, M. J., and Cleveland, D. W. (1989) J. Cell Biol. 108, 579-593 [Medline]
  25. Julien, J.-P., Tretjakoff, I., Beaudet, L., and Peterson, A. (1987) Genes & Dev. 1, 1085-1095 [Medline]
  26. Monteiro, M. J., Hoffman, P. N., Gearhart, J. D., and Cleveland, D. W. (1990) J. Cell Biol. 111, 1543-1557 [Medline]
  27. Beaudet, L., Charron, G., Houle, D., Tretjakoff, I., and Peterson, A. (1992) Gene (Amst.) 116, 205-214 [Medline]
  28. Rossant, J., Zirngibl, R., Cado, D., Shago, M., and Giguere, V. (1991) Genes & Dev. 5, 1333-1344 [Medline]
  29. Brinster, R. L., Chen, H. Y., Trumbauer, M., Senear, A. W., Warren, R., and Palmiter, R. D. (1981) Cell 27, 223-231 [Medline]
  30. Julien, J.-P., Beaudet, L., Tretjakoff, I., and Peterson, A. (1990) J. Physiol. (Paris) 84, 50-52
  31. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159
  32. Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., and Green, M. R. (1984) Nucleic Acids Res. 12, 7035-7056 [Medline]
  33. Bonnerot, C., Grimber, G., Briand, P., and Nicolas, J. F. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6331-6335 [Medline]
  34. Cohen-Tannoudji, M., Morello, D., and Babinet, C. (1992) Mol. Reprod. Dev. 33, 149-159 [Medline]
  35. Grosveld, F., Blom van Assendelft, G., Greaves, D. R., and Kollias, G. (1987) Cell 51, 975-985 [Medline]
  36. Kothary, R., Clapoff, S., Brown, A., Campbell, R., Peterson, A., and Rossant, J. (1988) Nature 335, 435-437 [Medline]
  37. Tuggle, C. K., Zakany, J., Cianetti, L., Peschle, C., and Chi Nguyen-huu, M. (1990) Genes & Dev. 4, 180-189 [Medline]
  38. Logan, C., Khoo, W. K., Cado, D., and Joyner, A. L. (1993) Development 117, 905-916 [Medline]
  39. Grunstein, M. (1990) Trends Genet. 6, 395-400 [Medline]
  40. Charron, G., Julien, J.-P., and Bibor-Hardy, V. (1995) J. Biol. Chem. 270, 25739-25745 [JBC]
  41. Yazdanbaksh, K., Fraser, P., Kioussis, D., Vidal, M., Grosveld, F., and et Lindenbaum, M. (1993) Nucleic Acids Res. 21, 455-461 [Medline]
  42. Fuchs, E., and Weber, K. (1994) Annu. Rev. Biochem. 63, 345-382 [Medline]
  43. Zimmerman, L., Lendahl, U., Cunningham, M., McKay, R., Parr, B., Gavin, B., Mann, J., Vassileva, G., and McMahon, A. (1994) Neuron 12, 11-24 [Medline]
  44. Xin, J.-H., Cowie, A., Lachance, P., and Hassell, J. A. (1992) Genes & Dev. 6, 481-496 [Medline]
  45. Janknecht, R., and Nordheim. A. (1993) Biochim. Biophys. Acta 1155, 346-356
  46. Zopf, D., Dineva, B., Betz, H., and Gundelfinger, E. D. (1990) Nucleic Acids Res. 18, 521-529 [Medline]
  47. Desmarais, D., Filion, M., Lapointe, L., and Royal, A. (1992) EMBO J. 11, 2971-2980 [Medline]
  48. Johnson, W. A., McCormick, C. A., Bray, S. J., and Hirsh, J. (1989) Genes & Dev. 3, 676-686 [Medline]
  49. Bray, S. J., Johnson, W. A., Hirsh, J., Heberlein, U., and Tjian, R. (1988) EMBO J. 7, 177-188 [Medline]
  50. Matter-Sadzinski, L., Hernandez, M.-C., Roztocil, T., Ballivet, M., and Matter, J.-P. (1992) EMBO J. 11, 4529-4538 [Medline]
  51. Danciger, E., Mettling, C., Vidal, M., Morris, R., and Margolis, F. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8565-8569 [Medline]
  52. Sakimura, K., Kushiya, E., Takahashi, T., and Suzuki Y. (1987) Gene (Amst.) 60, 107-113
  53. Vandaele, S., Nordquist, D. T., Feddersen, R. M., Tretjakoff, I, Peterson, A. C., and Orr, H. T. (1991) Genes & Dev. 5, 1136-1148 [Medline]
  54. Mori, N., Stein, R., Sigmund, O., and Anderson, D. J. (1990) Neuron 4, 583-594 [Medline]
  55. Maue, R. A., Kraner, S. D., Goodman, R. H., and Mandel, G. (1990) Neuron 4, 223-231 [Medline]
  56. Pospelov, V. A., Pospelova, T. V., and Julien, J.-P. (1994) Cell Growth & Differ. 5, 187-196 [Medline]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.